BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 17482783)

  • 1. Complexation of tanshinone IIA with 2-hydroxypropyl-beta-cyclodextrin: effect on aqueous solubility, dissolution rate, and intestinal absorption behavior in rats.
    Wang L; Jiang X; Xu W; Li C
    Int J Pharm; 2007 Aug; 341(1-2):58-67. PubMed ID: 17482783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of effect of beta-cyclodextrin and its water-soluble derivatives on in vitro drug transport across rat intestinal epithelium.
    Zheng Y; Zuo Z; Chow AH
    Int J Pharm; 2006 Feb; 309(1-2):123-8. PubMed ID: 16359834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Formulation and biological evaluation of glimepiride-cyclodextrin-polymer systems.
    Ammar HO; Salama HA; Ghorab M; Mahmoud AA
    Int J Pharm; 2006 Feb; 309(1-2):129-38. PubMed ID: 16377107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of dissolution and oral bioavailability of gliquidone with hydroxy propyl-beta-cyclodextrin.
    Sridevi S; Chauhan AS; Chalasani KB; Jain AK; Diwan PV
    Pharmazie; 2003 Nov; 58(11):807-10. PubMed ID: 14664337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inclusion complex of trimethoprim with beta-cyclodextrin.
    Li N; Zhang YH; Wu YN; Xiong XL; Zhang YH
    J Pharm Biomed Anal; 2005 Sep; 39(3-4):824-9. PubMed ID: 16011886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo evaluation of an amylobarbitone/hydroxypropyl-beta-cyclodextrin complex prepared by a freeze-drying method.
    Fathy M; Sheha M
    Pharmazie; 2000 Jul; 55(7):513-7. PubMed ID: 10944779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement of dissolution properties of furosemide by complexation with beta-cyclodextrin.
    Ozdemir N; Ordu S
    Drug Dev Ind Pharm; 1998 Jan; 24(1):19-25. PubMed ID: 15605593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Availability of phenindione-beta-cyclodextrin inclusion complex.
    Tous SS; el-Sayed AM; el-Harras SA; Jun HW
    Pharmazie; 1992 May; 47(5):365-8. PubMed ID: 1409827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of the 13-cis-retinoic acid/cyclodextrin inclusion complexes by phase solubility, photostability, physicochemical and computational analysis.
    Yap KL; Liu X; Thenmozhiyal JC; Ho PC
    Eur J Pharm Sci; 2005 May; 25(1):49-56. PubMed ID: 15854800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preparation and characterization of inclusion complexes of prazosin hydrochloride with beta-cyclodextrin and hydroxypropyl-beta-cyclodextrin.
    Liu L; Zhu S
    J Pharm Biomed Anal; 2006 Jan; 40(1):122-7. PubMed ID: 16095859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydroxypropyl methylcellulose microspheres with piroxicam and piroxicam-hydroxypropyl-beta-cyclodextrin inclusion complex.
    Jug M; Bećirević-Laćan M; Cetina-Cizmek B; Horvat M
    Pharmazie; 2004 Sep; 59(9):686-91. PubMed ID: 15497750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preparation and study on the inclusion complexes of two tanshinone compounds with beta-cyclodextrin.
    Yuexian F; Junfen L; Chuan D
    Spectrochim Acta A Mol Biomol Spectrosc; 2005 Jan; 61(1-2):135-40. PubMed ID: 15556431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Solid-state characterization and dissolution properties of naproxen-arginine-hydroxypropyl-beta-cyclodextrin ternary system.
    Mura P; Bettinetti GP; Cirri M; Maestrelli F; Sorrenti M; Catenacci L
    Eur J Pharm Biopharm; 2005 Jan; 59(1):99-106. PubMed ID: 15567306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study of insolubility problems of dexamethasone and digoxin: cyclodextrin complexation.
    Dilova V; Zlatarova V; Spirova N; Filcheva K; Pavlova A; Grigorova P
    Boll Chim Farm; 2004; 143(1):20-3. PubMed ID: 15085571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of parenteral formulation for a novel angiogenesis inhibitor, CKD-732 through complexation with hydroxypropyl-beta-cyclodextrin.
    Kim JH; Lee SK; Ki MH; Choi WK; Ahn SK; Shin HJ; Hong CI
    Int J Pharm; 2004 Mar; 272(1-2):79-89. PubMed ID: 15019071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of pH and complexation on transdermal permeation of gliquidone.
    Sridevi S; Diwan PV
    Pharmazie; 2002 Sep; 57(9):632-4. PubMed ID: 12369452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Study on preparation of the inclusion compound of curcumin with beta-cyclodextrin].
    Han G; Xu J; Li W; Ning C
    Zhong Yao Cai; 2004 Dec; 27(12):946-8. PubMed ID: 15807250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of cyclodextrin complexation on piroxicam gel formulations.
    Jug M; Bećirević-Laćan M; Kwokal A; Cetina-Cizmek B
    Acta Pharm; 2005 Sep; 55(3):223-36. PubMed ID: 16375834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Solubilization and complexation of the antileukotrienic drug Quinlukast in aqueous solutions of cyclodextrins].
    Kopecký F; Kopecká B
    Ceska Slov Farm; 2005 May; 54(3):137-40. PubMed ID: 15945461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physico-chemical characterization of disoxaril-dimethyl-beta-cyclodextrin inclusion complex and in vitro permeation studies.
    Ventura CA; Giannone I; Musumeci T; Pignatello R; Ragni L; Landolfi C; Milanese C; Paolino D; Puglisi G
    Eur J Med Chem; 2006 Feb; 41(2):233-40. PubMed ID: 16387393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.